Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bali, the first province to report a case of HIV in 1987, was placed sixth among Indonesian provinces with the highest cumulative number of HIV cases in 2017. As a popular tourist destination, the spread of genetic variants of HIV through international travel may become a cause for concern in Bali. Tourism is mostly concentrated in south Bali; thus, HIV in less popular regions in north Bali, such as Buleleng Regency, may have viral characteristics different from that in south Bali. Forty-three protease (PR), 40 reverse transcriptase (RT), 27 , and 23 genes were sequenced from 48 samples derived from antiretroviral treatment-experienced individuals. Subtyping revealed CRF01_AE as the dominant circulating recombinant form of HIV-1 in north Bali. Although no major mutation was detected in PR genes, several major mutations were identified in 4 out of the 40 RT genes (10%), indicating the emergence of HIV-1 drug resistance in this region.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/aid.2019.0058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.
Lancet HIV
September 2025
Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address:
Background: Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.
Methods: In this open-label non-inferiority trial conducted in Port-au-Prince, Haiti, adults (aged 18 years or older) with viral suppression (HIV-1 RNA <200 copies per mL) on second-line regimens including ritonavir-boosted protease inhibitors and two NRTIs were randomised (1:1) using a computer-generated random-number list.
Next-Generation Sequencing Analysis for HIV-1 Genotyping and Drug Resistance Mutations Mapping in Sicily, Italy.
Viruses
August 2025
Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties "G D'Alessandro", University of Palermo, 90133 Palermo, Italy.
Background: The advent and continuous improvement in antiretroviral therapy (ART) have profoundly altered the clinical course of HIV infection, shifting the focus from AIDS-related complications to the management of age-related comorbidities and non-AIDS-related hospitalizations. In this evolving context, optimizing ART is essential, with genotypic resistance testing (GRT), particularly through next-generation sequencing (NGS), playing a pivotal role.
Methods: This multicenter, retrospective cross-sectional study investigated HIV-1 subtypes, resistance mutations, and drug resistance profiles among 367 people living with HIV (PLWH) in Sicily, based on 384 GRTs performed at the Microbiology Laboratory of the University Hospital of Palermo.
Objective: To compare BMI-for-age z-score (zBMI) changes in treatment-experienced children and young people living with HIV aged 6 to <25 years on tenofovir alafenamide fumarate (TAF) to those on tenofovir disoproxil fumarate (TDF) and abacavir (ABC).
Methods: Cohort study of children and young people living with HIV from 12 European countries were grouped by drug exposure: 1 - on TAF with prior TDF use; 2 - on TAF no prior TDF; 3 - on TDF; and 4 - on ABC. Outcomes, adjusted for characteristics at drug start, were (i) incidence of overweight or obesity by 96 weeks, (ii) zBMI change 48 weeks before/after drug start, (iii) association between TAF/TDF/ABC and anchor drug on zBMI change and (iv) factors associated with zBMI change on TAF over 96 weeks.
Blood pressure, weight change and incident hypertension after switching to dolutegravir in treatment-experienced people living with HIV.
AIDS
July 2025
Institute for Global Health, University Heidelberg, Heidelberg, Germany.
Objective: Dolutegravir (DTG) is recommended in WHO guidelines and has reportedly been associated with excess gain in body weight (BW).
Design: In the prospective LighTen Cohort Study (ClinicalTrials.gov NCT02381275) we evaluated changes in BW and blood pressure (BP) of people living with HIV (PLHIV) who had initiated tenofovir (TDF)/lamivudine (3TC)/efavirenz (EFV; TLE).
Safe Switch to an Oral Two-Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV-1: An Observational Multicenter Study.
Health Sci Rep
July 2025
Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital and DIBIC University of Milan Milan Italy.
Background And Aims: People with vertically acquired HIV-1 are exposed to antiretroviral drugs throughout their lives. Two-drug regimens based on dolutegravir (DTG) are increasingly popular, showing excellent safety and efficacy and giving the opportunity to reduce toxicity and drug burden. However, studies reporting experience in this special population are still lacking.
View Article and Find Full Text PDF